IDYA

AI MemoPost-earnings T+3

IDEAYA Biosciences

As of 2026-08-06/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

ESMO clinical data updates • 2026-10-31

Base target: $37 / p=50% prob

Biggest risk

The lead program still faces regulatory and launch-execution risk, overall-survival data remain immature until a planned 2027 update, and multiple pipeline programs increase execution complexity. Secondary earnings coverage showed no actual Q2 EPS or revenue figures, so no surprise or miss can be confirmed. The only identified Truist target change, to $63 from $65, was dated July 7 and preceded the earnings release; no post-print analyst revision was identified.

Invalidation

Break below $25 or thesis failure.

What would change my mind?

OptimUM-02 produced a strong reported efficacy signal, the NDA/RTOR path is advancing, cash and securities were approximately $1.24 billion at June 30 with runway guidance into 2030 unchanged, and ESMO plus Roche-linked pipeline updates provide several 2026 value inflection points [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-06

Base target

$37

p=50%

Bull target

$52

p=20%

Bear target

$25

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Initial post-earnings reaction was modestly negative
Pipeline expansion and Roche collaboration
OptimUM-02 produced a strong reported efficacy signal, the NDA/RTOR path is advancing, cash and securities were approximately $1.24 billion at June 30 with runway guidance into 2030 unchanged, and ESMO plus Roche-linked pipeline updates provide several 2026 value inflection points [#SEC-8K-2026-08-04].

BearKey bullets

Binary clinical readout and enrollment or execution risk across IDE849, IDE892, IDE034, and related combinations.
Financing and dilution sensitivity despite the stated cash runway into 2030.
Overall-survival data for OptimUM-02 remain immature, leaving durability unresolved.

WatchKey bullets

ESMO clinical data updates

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $37 (p=50%)

Target spread vs base: +41% / -32%

Scenario probabilities

Bull Target: $52 (p=20%)Base Target: $37 (p=50%)Bear Target: $25 (p=30%)

Commentary

The Aug. 4 primary-source Q2 update is mildly positive on clinical progress, the NDA path, Roche collaboration, and liquidity [#SEC-8K-2026-08-04]. Secondary market coverage showed a $35.93 close, down 2.20%, and $36.26 extended trading, up 0.90%; actual EPS and revenue were listed as unavailable, preventing a confirmed surprise assessment. No post-print analyst revision was identified; the available Truist target cut to $63 from $65 preceded earnings. Social coverage is absent, so the negative deterministic prior supports monitoring rather than a high-conviction long.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Initial post-earnings reaction was modestly negative
Pipeline expansion and Roche collaboration

Scenarios

Bull Target (Scenario probability)

$52 / p=20% prob

Base Target (Scenario probability)

$37 / p=50% prob

Bear Target (Scenario probability)

$25 / p=30% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
ESMO clinical data updates
IDEAYA plans updated OptimUM-01 uveal-melanoma data and IDE849 DLL3 TOP1 ADC data at ESMO in October 2026, creating meaningful but binary clinical readout risk [#SEC-8K-2026-08-04].
Prob 60.00% • Move 12.00% • Priced-in 40.00%
EVENT2026-12-31
Darovasertib NDA submission path
OptimUM-02 met its primary endpoint, and IDEAYA says its NDA filing under the real-time oncology review program is underway with completion expected in H2 2026 [#SEC-8K-2026-08-04].
Prob 70.00% • Move 15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Initial post-earnings reaction was modestly negative
2026-08-31
Secondary market coverage showed a $35.93 close, down 2.20%, followed by a $36.26 extended-hours indication, up 0.90%. The same coverage listed actual Q2 EPS and revenue as unavailable, so no supported earnings surprise can be established. The deterministic prior remains negative across 5-120 day horizons [#SEC-8K-2026-08-04].
Prob 60% • Move -6% • Priced-in 65%

Long-term Catalysts

Months to a year

Pipeline expansion and Roche collaboration
2026-12-31
The company announced a Roche collaboration for IDE892 plus RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer, targets a Phase 1 combination trial in H2 2026, and plans a Q4 R&D Day [#SEC-8K-2026-08-04].
Prob 50% • Move 10% • Priced-in 25%

Risks

Binary clinical readout and enrollment or execution risk across IDE849, IDE892, IDE034, and related combinations.
Financing and dilution sensitivity despite the stated cash runway into 2030.
Overall-survival data for OptimUM-02 remain immature, leaving durability unresolved.
Q2 actual EPS and revenue, earnings surprise, and post-print estimate revisions remain unavailable or unconfirmed.
Regulatory review, NDA timing, and potential approval or label limitations for darovasertib.
The initial post-earnings price reaction was modestly negative, while the available analyst target reduction predates the print.

Peers

Symbol	Summary
RCUS	Closest listed oncology-oriented peer in the packet, but modality, pipeline maturity, and clinical assets differ materially; useful mainly for SMID-cap oncology sentiment context.
LEGN	Oncology-focused biotech with a different cell-therapy modality and commercial profile, making it a loose rather than direct operating comp.
ALMS	Similar-capitalization clinical-stage biotech, but indication and modality overlap with IDEAYA are limited; mainly a risk-appetite and financing comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

RCUS

Closest listed oncology-oriented peer in the packet, but modality, pipeline maturity, and clinical assets differ materially; useful mainly for SMID-cap oncology sentiment context.

LEGN

Oncology-focused biotech with a different cell-therapy modality and commercial profile, making it a loose rather than direct operating comp.

ALMS

Similar-capitalization clinical-stage biotech, but indication and modality overlap with IDEAYA are limited; mainly a risk-appetite and financing comp.